Business · Companies · 8 hrs ago
Rubió’s sales rose 8% to €195 million in 2025
Rubió's sales rose 8% to €195 million in 2025, as the pharmaceutical group based in Castellbisbal, Spain, grew more slowly than in previous years.
The family-owned company earned €5.2 million in profit, down 5% from a year earlier as financing and tax costs increased.
Its operating profit rose 10% to €9.2 million.
Rubió has expanded through acquisitions, investment in research and development, and new business areas, and raised investment nearly 60% to €13 million last year.
It operates in more than 70 countries, where sales reached €33 million, up 32%.
Rubió expects sales to reach about €220 million this year, a projected increase of 13% from 2025.
Rubió’s revenue rose 8% to €195 million in 2025, exceeding its €193 million sales forecast.
The pharmaceutical group earned €5.2 million, down 5% from the previous year.
Operating profit increased 10% to €9.2 million.
The company increased investment by nearly 60% to €13 million.
Rubió expects revenue to reach about €220 million this year, a 13% increase.
- Who
- Rubió, a pharmaceutical group.
- What
- Revenue rose 8% to €195 million in 2025.
- When
- In 2025; the results were reported on November 3, 2026.
- Where
- Rubió is based in Castellbisbal, in Vallès Occidental, Spain.
- Why
- The sources cite acquisitions, increased research and development investment, stronger international presence and new business lines as factors behind the group’s accelerated growth in recent years.
This story does not have two clearly opposing sides.
Rubió’s revenue rose 8% to €195 million, while its profit fell 5% to €5.2 million.
Rubió forecast revenue of about €220 million, a 13% increase.
- 2025 revenue
- €195 million
- Revenue growth
- 8%
- Net profit
- €5.2 million, down 5%
- Operating profit
- €9.2 million, up 10%
- Investment
- €13 million, up nearly 60%
- 2026 revenue forecast
- About €220 million